Vivesto completes recruitment in Paccal Vet study in cats
The study determined the maximum tolerated dose, with anti-tumor effects observed in 21 cats.
See the latest news and media coverage for Vivesto. We track all announcements, press releases, and industry mentions in real time, all in one place.
Swedish oncology drug development company
vivesto.comLast updated
In short: Vivesto reported progress in its oncology pipeline, completed a reverse share split, and narrowed losses during its second quarter.
The study determined the maximum tolerated dose, with anti-tumor effects observed in 21 cats.
Topline results expected Q3 2026. The study evaluates Paccal Vet in dogs with splenic hemangiosarcoma.
The study shows Cantrixil was well tolerated intravenously in dogs, supporting development toward Phase I in AML.
He will take up the role on July 1, 2026, succeeding Robert Maiorana.
Solna, Sweden, September 15, 2026 - Vivesto AB, an oncology-focused development company, today announced positive topline results from its open label clinical pilot study evaluating...
Close The stock exchange opens green - Embracer surges on report. Market watch with Helena Yohannes Magnusson The drug development company Vivesto reports a reduced loss in the second quarter, while...
Visit a quote page and your recently viewed tickers will be displayed here.
At close: 17 April at 16:00:00 GMT-4...
Track Vivesto and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Vivesto and other trending companies.